Amgen deCODE Genetics Takes Part in Its First Mission Week in Iceland
Oct 16, 2025 | NEWS
Last week, Amgen deCODE Genetics (ADG) participated for the first time in Amgen’s Mission Week — an annual initiative where employees around the world pause to reflect on the purpose of their work and the impact it can have on the lives of others. Throughout the week,...
Running with Purpose: deCODE Team Joins Reykjavik Marathon to Make a Difference
Aug 26, 2025 | NEWS
On August 23, seventeen employees from deCODE took part in the Reykjavik Marathon, each running in support of various charities through pledge donations. Together, they raised awareness and funds for organizations that make a difference in the lives of people and...
Lethal mutations in pregnancy loss
May 21, 2025 | NEWS
In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to new mutations in the fetus. In other words, millions of pregnancies...
DECODE ANNOUNCES NEW LEADERSHIP UPDATES
May 2, 2025 | deCODE genetics, NEWS
Kari Stefánsson, M.D., Dr. Med., Tenure Ends; Two Distinguished Genetic Researchers in Iceland Appointed Co-Managing Directors deCODE genetics today announced leadership changes. The tenure of Kari Stefánsson, M.D., Dr. Med., founder and chief executive officer of...
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.